AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Mayne Pharmaâs net profit fell to negative $133.9 million despite recording strong performance in the second half of 2018. In 2H18 the âreportedâ EBITDA increased 307% on 1H18, reflecting benefits derived from generic products performance growth, portfolio optimization, and cost savings.
But bringing first half and second half results together for the period ended 30 June 2018, companyâs revenue slipped 7%, gross profit down 19% and reported EBITDA declined by 48% on prior year. Reported net loss after tax was $133.9 million compared to $88.6 million profit in FY17.
[optin-monster-shortcode id="wxhmli4jjedneglg1trq"]
 The companyâs negative results mainly relate to one off transactions including stock obsolescence, impact of US tax reforms, restructuring expenses and asset impairments incurred in first half 2018.
No dividend has been declared for the fiscal year ended 30 June 2018.
Despite posting overall loss for FY18, second half year performance popped up Mayneâs stock by daily price change of +5.714% to trade at $1.110 on ASX today, i.e. 24 August 2018.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a companyâs prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkineâs team of analysts bought you handpicked report for âTop 25 Dividend Stocks For 2018.â
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
